Movement Alert｜3SBio Rises 5.32% in Regular Trading, Chairman Stake Increase Combined with Medical Insurance Catalog Adjustment Boost Sentiment

Market Focus06-10

On June 10, 3SBio rose 5.32% in regular trading, trading at HK$16.4/share, with trading volume of approximately HK$300 million. The stock had previously touched its 52-week low of HK$15.50.

Multiple catalysts converged to drive the rebound. Chairman and CEO Lou Jing purchased 516,000 shares on June 8 at HK$15.2497 per share, totaling approximately HK$7.87 million, bringing his stake to 21.03%. Meanwhile, China launched a new round of national medical insurance catalog adjustments, drawing renewed market attention to the company's innovative pipeline.

The company's PD-1/VEGF bispecific antibody SSGJ-707, licensed to Pfizer with a US$1.5 billion upfront payment and US$6.05 billion total deal value, demonstrated strong Phase II clinical data with a confirmed ORR of 67.6% in PD-L1-positive NSCLC patients. Additionally, the board authorized directors to repurchase up to 10% of issued shares, providing further price support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160330580?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 11:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160330580","market":"us","top_or_hot":-1,"title":"Movement Alert｜3SBio Rises 5.32% in Regular Trading, Chairman Stake Increase Combined with Medical Insurance Catalog Adjustment Boost Sentiment","media":"Market Focus","content":"<p><p>On June 10, 3SBio rose 5.32% in regular trading, trading at HK$16.4/share, with trading volume of approximately HK$300 million. The stock had previously touched its 52-week low of HK$15.50.</p><p>Multiple catalysts converged to drive the rebound. Chairman and CEO Lou Jing purchased 516,000 shares on June 8 at HK$15.2497 per share, totaling approximately HK$7.87 million, bringing his stake to 21.03%. Meanwhile, China launched a new round of national medical insurance catalog adjustments, drawing renewed market attention to the company's innovative pipeline.</p><p>The company's PD-1/VEGF bispecific antibody SSGJ-707, licensed to Pfizer with a US$1.5 billion upfront payment and US$6.05 billion total deal value, demonstrated strong Phase II clinical data with a confirmed ORR of 67.6% in PD-L1-positive NSCLC patients. Additionally, the board authorized directors to repurchase up to 10% of issued shares, providing further price support.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜3SBio Rises 5.32% in Regular Trading, Chairman Stake Increase Combined with Medical Insurance Catalog Adjustment Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜3SBio Rises 5.32% in Regular Trading, Chairman Stake Increase Combined with Medical Insurance Catalog Adjustment Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-10 11:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 10, 3SBio rose 5.32% in regular trading, trading at HK$16.4/share, with trading volume of approximately HK$300 million. The stock had previously touched its 52-week low of HK$15.50.</p><p>Multiple catalysts converged to drive the rebound. Chairman and CEO Lou Jing purchased 516,000 shares on June 8 at HK$15.2497 per share, totaling approximately HK$7.87 million, bringing his stake to 21.03%. Meanwhile, China launched a new round of national medical insurance catalog adjustments, drawing renewed market attention to the company's innovative pipeline.</p><p>The company's PD-1/VEGF bispecific antibody SSGJ-707, licensed to Pfizer with a US$1.5 billion upfront payment and US$6.05 billion total deal value, demonstrated strong Phase II clinical data with a confirmed ORR of 67.6% in PD-L1-positive NSCLC patients. Additionally, the board authorized directors to repurchase up to 10% of issued shares, providing further price support.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1160330580","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160330580","pubTimestamp":1781062014,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 10, 3SBio rose 5.32% in regular trading, trading at HK$16.4/share, with trading volume of approximately HK$300 million. The stock had previously touched its 52-week low of HK$15.50.Multiple...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"动向提示|三生制药常规盘涨5.32%董事长增持叠加医保目录调整提振人气","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"On June 10, 3SBio rose 5.32% in regular trading, trading at HK$16.4/share, with trading volume of approximately HK$300 million. The stock had previously touched its 52-week low of HK$15.50.Multiple catalysts converged to drive the rebound. Chairman and CEO Lou Jing purchased 516,000 shares on June 8 at HK$15.2497 per share, totaling approximately HK$7.87 million, bringing his stake to 21.03%. Meanwhile, China launched a new round of national medical insurance catalog adjustments, drawing renewed market attention to the company's innovative pipeline.The company's PD-1/VEGF bispecific antibody SSGJ-707, licensed to Pfizer with a US$1.5 billion upfront payment and US$6.05 billion total deal value, demonstrated strong Phase II clinical data with a confirmed ORR of 67.6% in PD-L1-positive NSCLC patients. Additionally, the board authorized directors to repurchase up to 10% of issued shares, providing further price support.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160330580","isCrawlerRequest":true}